ArQule Says Combination Cancer Study Encouraging
Posted on: Friday, 10 November 2006, 09:00 CST
ArQule has said that data from a phase Ib combination therapy trial with ARQ 501 and docetaxel supports previous findings demonstrating clinical tolerability and promising signs of anti-tumor activity in cancer patients.
The phase I study evaluated patients with advanced solid tumors who had failed prior treatments with a range of anticancer therapies.
A total of 43 patients have received the combination therapy of ARQ 501 and docetaxel in this trial with different doses of ARQ 501. Promising anti-tumor activity has been observed over the range of doses administered. Of 36 patients evaluable for efficacy, 20 achieved disease stabilization, and evidence of tumor regression was observed in 4 of these patients, 3 of whom had a partial response and 1 of whom had a minor response.
The most common adverse events were anemia, fatigue, hyperbilirubinemia and leucopenia.
"These data confirm the potential of ARQ 501 when used as combination therapy with chemotherapeutic agents," said Dr Stephen Hill, president and CEO of ArQule.
ARQ 501 is being developed under an alliance with Roche. The company's phase II clinical program with ARQ 501 consists of three separate trials, including two monotherapy trials, in leiomyosarcoma and head and neck cancer, and one combination therapy trial, with gemcitabine in pancreatic cancer.
Source: Datamonitor
Related Articles
- ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
- ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
- Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
- Thallion Enrolls First Patient in TLN-4601 Phase II Trial
- Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
- Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- Ecopia to Include Pancreatic Cancer Patients in Its Ongoing Phase I Clinical Trial
- Favrille Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial of FavId for Follicular B-Cell Non-Hodgkin's Lymphoma
- Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients With Hormone Dependent Prostate Cancer
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds